Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May 16;12(5):e8156.
doi: 10.7759/cureus.8156.

Valacyclovir-Induced Thrombotic Thrombocytopenic Purpura

Sumera Bukhari  1 , Hafiz M Aslam  2 , Talha A Awwal  3 , Donald Christmas  2 , Sara L Wallach  2
Affiliations
Case Reports

Valacyclovir-Induced Thrombotic Thrombocytopenic Purpura

Sumera Bukhari et al. Cureus. .

Abstract

Valacyclovir is a well-tolerated antiviral drug. Thrombotic thrombocytopenic purpura is a rare adverse effect of valacyclovir therapy. Mostly, it has been reported in clinical trials and case reports in patients with high dose or low dose therapy in immunocompromised patients. Herein we write a case report of the immunocompetent patient, who was taking very low dose valacyclovir therapy for his recurrent genital herpes. This case emphasizes the role of low dose (1000 mg/day) valacyclovir therapy causing thrombotic thrombocytopenic purpura in an immunocompetent patient with no other explainable trigger.

Keywords: thrombotic thrombocytopenic thrombocytopenia; ttp; valacyclovir.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. New antiherpesvirus agents. Their targets and therapeutic potential. Alrabiah FA, Sacks SL. Drugs. 1996;52:17–32. - PubMed
    1. Highlights of prescribing information. [May;2020 ];https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020487s016lbl.pdf 2020
    1. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204) Bell WR, Chulay JD, Feinberg JE. Medicine (Baltimore) 1997;76:369–380. - PubMed
    1. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. Rivaud E, Massiani MA, Vincent F, Azoulay E, Coudrec LJ. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/525291. Arch Intern Med. 2000;160:1705–1706. - PubMed
    1. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Amorosi EL, Ultmann JE. Medicine. 1966;45:139–160.

Publication types

LinkOut - more resources